Envestnet Asset Management Inc. Has $295.12 Million Stake in AstraZeneca PLC $AZN

Envestnet Asset Management Inc. boosted its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 8.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,846,667 shares of the company’s stock after buying an additional 293,113 shares during the period. Envestnet Asset Management Inc.’s holdings in AstraZeneca were worth $295,116,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AZN. Chapin Davis Inc. raised its position in AstraZeneca by 3.3% in the third quarter. Chapin Davis Inc. now owns 3,795 shares of the company’s stock worth $291,000 after purchasing an additional 120 shares in the last quarter. CoreCap Advisors LLC grew its stake in shares of AstraZeneca by 30.6% in the 3rd quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock valued at $41,000 after purchasing an additional 125 shares during the period. Highline Wealth Partners LLC raised its holdings in shares of AstraZeneca by 32.0% in the 3rd quarter. Highline Wealth Partners LLC now owns 532 shares of the company’s stock worth $41,000 after buying an additional 129 shares in the last quarter. Traub Capital Management LLC lifted its position in shares of AstraZeneca by 3.3% during the 3rd quarter. Traub Capital Management LLC now owns 4,115 shares of the company’s stock worth $316,000 after buying an additional 130 shares during the period. Finally, Aaron Wealth Advisors LLC lifted its position in shares of AstraZeneca by 0.6% during the 3rd quarter. Aaron Wealth Advisors LLC now owns 21,215 shares of the company’s stock worth $1,628,000 after buying an additional 136 shares during the period. 20.35% of the stock is owned by institutional investors.

AstraZeneca Trading Up 1.8%

Shares of NASDAQ AZN opened at $187.68 on Thursday. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $192.79. The company has a 50-day moving average of $97.93 and a two-hundred day moving average of $86.84. The company has a market cap of $582.15 billion, a PE ratio of 62.35, a P/E/G ratio of 1.59 and a beta of 0.34. The company has a current ratio of 0.88, a quick ratio of 0.69 and a debt-to-equity ratio of 0.54.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Thursday, November 6th. The company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.05. AstraZeneca had a net margin of 16.17% and a return on equity of 32.89%. The business had revenue of $15.19 billion during the quarter, compared to analyst estimates of $14.75 billion. During the same quarter last year, the business posted $2.08 earnings per share. AstraZeneca’s revenue for the quarter was up 12.0% compared to the same quarter last year. As a group, equities analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on AZN. Wall Street Zen lowered AstraZeneca from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 17th. Morgan Stanley reiterated an “overweight” rating and set a $103.00 target price on shares of AstraZeneca in a research report on Wednesday, December 3rd. HSBC reaffirmed a “buy” rating and set a $108.00 price objective on shares of AstraZeneca in a research note on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of AstraZeneca in a research note on Friday, January 16th. Finally, TD Cowen restated a “buy” rating on shares of AstraZeneca in a research report on Tuesday, December 9th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $95.75.

AstraZeneca Company Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.